 |
|
|
| |
Opti-DOR: 48 week data on DOR/3TC/TDF as an alternative first-line antiretroviral therapy (ART) regimen to integrase inhibitors for people with HIV and BMI>25kg/m2 in a randomised phase 3b non-inferiority study
|
| |
| |
IAS 2026 Rio, Brazil
J. WOODS
published today
Initial HIV Therapy for Adults and Treatment-Associated Weight GainThe Opti-DOR Randomized Clinical Trial
Download the PDF here
|
| |
|
|
|
|
|
